Get the Stockscreener App
28.82
2.47%
0.695
Septerna Inc stock is traded at $28.82, with a volume of 200.30K.
It is up +2.47% in the last 24 hours and up +15.62% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$28.13
Open:
$28.6
24h Volume:
200.30K
Relative Volume:
0.67
Market Cap:
$1.29B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.88%
1M Performance:
+15.62%
6M Performance:
+104.14%
1Y Performance:
+367.94%
1-Day Range:
$27.50
$29.02
1-Week Range:
$26.58
$30.70
52-Week Range:
$4.66
$32.63
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
28.82 | 1.26B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Initiated | Truist | Buy |
| Nov-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-23-25 | Initiated | H.C. Wainwright | Buy |
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
View All
Septerna Inc Stock (SEPN) Latest News
SEPN: SEP-631 advances to phase II in CSU after robust phase I results; SEP-479 enters clinical trials - TradingView
SEPN: SEP-631 and SEP-479 advance with strong data, phase 2 and 1 trials planned, and pipeline growth - TradingView
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN), Payoneer (PAYO) and Porch Group (PRCH) - The Globe and Mail
A Look At Septerna (SEPN) Valuation After Recent Share Price Momentum And GPCR Pipeline Reassessment - Sahm
Septerna (SEPN) Receives Overweight Rating and Target Price Hike by Wells Fargo | SEPN Stock News - GuruFocus
[144] Septerna, Inc. SEC Filing - Stock Titan
Septerna (NASDAQ:SEPN) Price Target Raised to $40.00 at HC Wainwright - MarketBeat
Septerna Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Septerna Advances SEP-631 After Positive Phase 1 Results - TipRanks
SEPN: SEP-631 showed strong Phase 1 efficacy and safety, advancing to Phase 2 for urticaria in 2026 - TradingView
Septerna reports positive Phase 1 SEP-631 data; plans Phase 2b CSU study in 2H 2026 - TradingView
Positive SEP-631 trial data drives Phase 2 plan at Septerna (NASDAQ: SEPN) - Stock Titan
Septerna’s SEP-631 shows positive Phase 1 trial results - Investing.com Australia
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy - Bitget
Septerna says SEP-631 well-tolerated with adverse event profile comparable to placebo - marketscreener.com
Septerna Says SEP-631 Well-Tolerated With Adverse Event Profile Comparable To Placebo - TradingView
Septerna pill blocked induced skin wheals at low doses in Phase 1 test - Stock Titan
Sentiment Watch: Is Septerna Inc part of any ETFBear Alert & Free Community Consensus Stock Picks - baoquankhu1.vn
Why Septerna (SEPN) Is Up 6.4% After Surging GPCR Pipeline-Driven Revenue GrowthAnd What's Next - simplywall.st
Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Septerna, Inc. (SEPN) Stock Analysis: Unleashing a 12,113% Revenue Growth Amidst Biotech Innovations - DirectorsTalk Interviews
Zacks Research Upgrades Septerna (NASDAQ:SEPN) to Hold - MarketBeat
Aug Breakouts: Does Septerna Inc have a sustainable dividendMarket Trend Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Septerna stock reaches all-time high at 31.39 USD By Investing.com - Investing.com Australia
Septerna (NASDAQ:SEPN) Reaches New 12-Month HighStill a Buy? - MarketBeat
SEP-631 Phase 1 Readout: The Catalyst Set To Drive Septerna In 2026 (NASDAQ:SEPN) - Seeking Alpha
Septerna stock reaches all-time high at 31.39 USD - Investing.com
Will Septerna Inc outperform the market in YEAR2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Septerna to Present at TD Cowen 46th Annual Health Care Conference - Bitget
Biotech Septerna to webcast TD Cowen health talk on March 3 - Stock Titan
SEPNSepterna, Inc. Latest Stock News & Market Updates - Stock Titan
Septerna president Bhatt sells $115,860 in shares By Investing.com - Investing.com South Africa
Septerna, Inc. (SEPN) Stock Analysis: A Biotech Powerhouse With A 25% Upside Potential - DirectorsTalk Interviews
Septerna president Bhatt sells $115,860 in shares - Investing.com Nigeria
Insider Selling: Septerna (NASDAQ:SEPN) COO Sells 4,000 Shares of Stock - MarketBeat
Will Septerna Inc. announce a stock split2025 Technical Overview & Accurate Intraday Trading Signals - mfd.ru
Septerna (NASDAQ:SEPN) Trading Down 5.9%Here's What Happened - MarketBeat
Will Septerna Inc. stock return to pre crisis levelsMarket Growth Report & Accurate Entry and Exit Point Alerts - mfd.ru
Insiders See US$934.3k Investment In Septerna Jump Last Week - 富途牛牛
Septerna (NASDAQ:SEPN) Hits New 1-Year HighWhat's Next? - MarketBeat
Septerna Inc stock hits all-time high at 30.51 USD By Investing.com - Investing.com Canada
Septerna Inc stock hits all-time high at 30.51 USD - Investing.com India
Septerna (NASDAQ:SEPN) Shares Up 9.4%Here's What Happened - MarketBeat
Risk Analysis: How volatile is Septerna Inc stockPortfolio Growth Summary & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Investment Recap: Is Septerna Inc forming a bullish divergenceNew Guidance & Consistent Growth Stock Picks - baoquankhu1.vn
Published on: 2026-02-21 01:46:34 - mfd.ru
Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Pioneer With 31.43% Upside Potential - DirectorsTalk Interviews
Loss Report: Does Septerna Inc have a sustainable dividendMarket Risk Analysis & Safe Entry Point Alerts - baoquankhu1.vn
How Early SEP-631 Data at AAAAI 2026 Will Impact Septerna (SEPN) Investors - simplywall.st
Septerna Reports Inducement Grant under Nasdaq Listing Rule 5635(4) - marketscreener.com
Septerna to present phase 1 data for SEP-631 at AAAAI meeting - Investing.com Canada
Septerna Inc Stock (SEPN) Financials Data
There is no financial data for Septerna Inc (SEPN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):